Medicenna Therapeutics Corp.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| MDNA.TO | CHRS | HBP.TO | HOWL | BCTX | HURA | |
|---|---|---|---|---|---|---|
| Market cap | 40.15M | 131.36M | 70.27M | 52.98M | 27.86M | 109.61M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1.9 | -1.3 | -8.4 | -1.8 | -8.2 | -2.8 |
| Price/book | 24.2 | 2.2 | 4.8 | 3.3 | 1.7 | 6.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −70.81% | −42.95% | −54.68% | −12.30% | −67.55% | −29.80% |
| Today | +4.82% | +5.54% | 0.00% | +1.87% | +5.98% | +3.93% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All MDNA.TO news ›Medicenna Completes Phase 1/2 ABILITY-1 Enrollment and Announces Webinar to Discuss Updated MDNA11 Results with Key Opinion Leaders
As previously announced on October 5, 2026, updated data from ABILITY-1 will be presented by Prof. Paolo Ascierto, during an oral session at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting on November 7th, 2026. The…
Medicenna Therapeutics Announces Issuance and Allowance of New U.S. Patents Covering IL-4 and IL-13 Superkine Platforms Including Bizaxofusp
Published on 06/11/2026 at 07:17 am EDT U.S. Patent No. 12,503,496: ?Interleukin-4 Receptor-Binding Fusion Proteins and Uses Thereof? (Medicenna and the U.S. National Institutes of Health, co-owners). The issued patent covers the…
Medicenna Therapeutics Corp. Announces Oral Presentation of Topline Data from the Phase 1/2 Ability-1 Study of Mdna11 At Sitc 2026
Medicenna Therapeutics Corp. announced that an abstract reporting topline data from the Phase 1/2 study of MDNA11 has been selected for oral presentation at the Society for Immunotherapy of Cancer ... Biotechnology & Medical Research…
Medicenna Therapeutics Finalizes Terms of its Public Offering of Securities
Medicenna Therapeutics has finalized the terms of its previously-announced marketed underwritten public offering of securities of the company, being an offering of units at a price to the public... Biotechnology & Medical Research…
MediciNova CEO Provides Shareholder Update
3iQ Receives In-Principal Approval from Abu Dhabi's IFC MediciNova (MNOV) updated shareholders on its MN-001 Phase 2 trial, which did not achieve statistical significance on its primary endpoints. The double-blind portion of COMBAT-ALS,…
Medline to report third quarter 2026 results on November 4, 2026
Netlist and Micron Enter Patent License and Settlement Agreements Medline (MDLN) plans to report its third quarter 2026 financial results before the market opens on November 4, 2026. A webcast and conference call to discuss the results…
Medicenna Therapeutics Raises $4.4M Via Public Offering of Units
Medicenna Therapeutics closed its previously announced marketed public offering of units at $0.50 apiece, for about $4.44 million, before deducting offering expenses and excluding any proceeds the... Biotechnology & Medical Research…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com3
- stocktitan.net2
- investingnews.com1
- kalkinemedia.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.